[BioTimes] USCAREPHARM Co., Ltd. (CEO Seokjin Song), a company specializing in bio-medical aesthetics, announced on the 17th that it has been finally selected as a 2026 Global IP (Intellectual Property) Star Company, a program organized by the Korean Intellectual Property Office and Gyeonggi Province. The Global IP Star Company program selects promising small and medium-sized enterprises with strong export growth potential and provides them with customized, comprehensive intellectual property-based support over a three-year period. USCAREPHARM was selected in recognition of its technological capabilities in biodegradable polymer-based medical devices and the global expansion potential of its proprietary brands. USCAREPHARM is an R&D-driven company that has developed differentiated products in the fields of medical aesthetics and bio-healthcare based on its experience in pharmaceutical and healthcare research and development. Leveraging its accumulated core technologies, including ORTE® biodegradable microparticle technology and its development experience with Curing Hyaluronic Acid®, a solid cross-linked hyaluronic acid material, the company has continued to commercialize and market its technologies through its medical aesthetics brand ERBELLA®. Recently, USCAREPHARM has achieved tangible results in overseas markets such as Vietnam and Saudi Arabia, while also stepping up its entry into the South American market, further accelerating its global business expansion. Through this latest selection, the company plans to strengthen its IP competitiveness by further accelerating overseas patent filings and securing trademark and design rights. As a result of this selection, USCAREPHARM will receive intensive support over the next three years for securing intellectual property rights, including overseas patent applications and brand and design development. Based on this support, the company plans to strengthen its technological protection barriers as it expands into global aesthetics markets such as North America and Europe. A representative from USCAREPHARM stated, “Being selected as a Global IP Star Company is a meaningful achievement that officially recognizes our technological capabilities and global growth potential.” The representative added, “Moving forward, we will build on a strong intellectual property portfolio to grow into an innovative company leading the global bio-medical aesthetics market.”

2026.04.22

USCAREPHARM announced on the 25th that it has signed an exclusive distribution agreement in Vietnam for the ERBELLA Skin Booster Collection with REGENIX, a local Vietnamese company specializing in the distribution of medical devices. Under this agreement, REGENIX has secured exclusive distribution rights for ERBELLA Skin Booster products throughout Vietnam. Beyond simple product supply, the two companies have agreed to build a comprehensive partnership that includes local marketing, medical practitioner training, and the development of treatment protocols. The ERBELLA Skin Booster Collection offers a specialized product portfolio tailored to each indication, including brightening, hydration, anti-aging, and acne care. The products can be used in combination with drug delivery devices to maximize treatment efficacy, and customized treatment protocols can be designed according to each patient’s skin condition and needs. According to the company, local medical professionals in Vietnam have shown strong interest in the product lineup, which is capable of addressing the country’s diverse skin types and climate conditions. USCAREPHARM and REGENIX plan to roll out training and marketing activities for Vietnamese medical professionals in phases. They intend to hold regular seminars and hands-on workshops in major cities while expanding their local medical network. USCAREPHARM also plans to position Vietnam as a strategic hub for its Southeast Asian aesthetics business and pursue step-by-step expansion into neighboring countries. A representative from USCAREPHARM’s MA Division stated, “Vietnam is a key market where demand for aesthetic procedures is rapidly increasing. Through a long-term partnership with REGENIX, we will expand the presence of ERBELLA Skin Booster in the local market.” The representative added, “Rather than focusing solely on product exports, we aim to build a successful model in Vietnam based on a partnership that includes education and marketing, and use this as a foundation to expand our business across Southeast Asia.”

2026.03.25 17:47

USCAREPHARM’s MA Division participated in IMCAS Americas 2026, held in São Paulo, Brazil from March 13 to 15, 2026, where it introduced its global medical aesthetics brand ERBELLA. Through its participation, the company established strategic partnerships with local medical professionals and distributors, officially launching its efforts to enter the South American aesthetics market with Brazil as its regional hub. By taking part in IMCAS Americas 2026, one of the largest aesthetic medicine congresses in Latin America, USCAREPHARM’s MA Division took its first step toward expanding into the South American aesthetics market. IMCAS Americas is a prestigious conference attended by dermatologists, plastic surgeons, and aesthetic treatment professionals from across Latin America, serving as a key platform for identifying the latest technological trends and market developments. Through this event, USCAREPHARM directly introduced the strengths of the ERBELLA brand to local medical professionals and confirmed the strong interest in K-beauty medical aesthetic solutions. During the event, USCAREPHARM’s MA Division held intensive business meetings with major medical professionals and distribution companies from Brazil and other South American countries. Detailed discussions covered product supply systems, distribution channel development, and potential areas of collaboration. The company also explored ways to provide tailored solutions that reflect local skin characteristics and aesthetic needs. In particular, ERBELLA’s technology received strong recognition for its ability to align with local treatment trends that favor natural and gradual improvements. USCAREPHARM also used its participation in IMCAS Americas not simply as a product promotion opportunity, but as a comprehensive market research initiative for the South American aesthetics sector. The company closely analyzed skin characteristics, preferred treatment trends, medical environments, and regulatory systems in Brazil and across South America. Based on these on-site insights, it plans to develop a localized product portfolio and medical education programs for ERBELLA’s future launch in the South American market. USCAREPHARM’s MA Division plans to position Brazil as a key strategic base for its South American aesthetics business and pursue a phased market expansion strategy. While proceeding step by step with local regulatory and licensing procedures, the company also aims to strengthen professional training for medical practitioners through academic seminars and hands-on workshops in major cities. By continuing to participate in major global congresses and industry exhibitions, USCAREPHARM intends to further enhance brand awareness and establish itself as a total aesthetics solution partner offering not only products, but also treatment know-how and education. A representative from USCAREPHARM’s MA Division stated, “Brazil is the largest aesthetics market in South America and a key region leading global medical beauty trends. Through our participation in IMCAS Americas, we confirmed the positive response to ERBELLA products from local medical professionals and partners.” The representative added, “With a product portfolio and education programs optimized for the characteristics of the local market, we aim to grow ERBELLA into a leading aesthetics brand in South America and further elevate the global status of K-beauty aesthetics.”

2026.03.20 14:23